Publication
An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (7)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 7
- cancerB-Cell Malignant Neoplasmcivic_curation1.00
- cancerMelanomacivic_curation1.00
- drugJQEZ5civic_curation1.00
- geneBRAFcivic_curation1.00
- geneEZH2civic_curation1.00
- variantBRAF V600Ecivic_curation1.00
- variantEZH2 Y646Fcivic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27135738
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EZH2 Y646F3 | ||||||||
| (oncogenic) | B-Cell Malignant NeoplasmCURATED_BROADER | Oncogenic | D | Supports Oncogenicity | 4 | accepted | EID10394Ezh2 Y641F (EZH2 Y641F) was conditionally expressed in mouse B-cells and caused high-penetrance lymphoma that was further accelerated by Bcl2 overexpression or p53 loss (but not c-Myc overexpression).… (full text at CIViC) PMID 27135738 · Souroullas et al., 2016 · Open in CIViC | civic |
| JQEZ5 | B-Cell Malignant NeoplasmCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID11083CD19-Cre Ezh2 Y641F+ mice with lymphoma were treated with vehicle or 50mpk of JQEZ5 by daily intraperitoneal injection. Six days of treatment with JQEZ5 complete cleared the malignant population from … (full text at CIViC) PMID 27135738 · Souroullas et al., 2016 · Open in CIViC | civic |
| (prognostic) | Cutaneous MelanomaALIAS | Prognostic | D | Supports Poor Outcome | 5 | submitted | EID8036Conditional expression of mouse equivalent mutation Ezh2(Y641F) in melanocytes caused high penetrance melanoma PMID 27135738 · Souroullas et al., 2016 · Open in CIViC | civic |
| BRAF V600E + EZH2 Y646FEZH2BRAF1 | ||||||||
| JQEZ5 | Melanoma | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID6952Experiment with immunodeficient mice transplanted with melanoma cell lines indicates EZH2 inhibitor JQEZ5 might be effective in combination with a B-RAF inhibitor in RAF-mutant melanoma. PMID 27135738 · Souroullas et al., 2016 · Open in CIViC | civic |
| EZH2 Y6461 | ||||||||
| Dabrafenib + GSK126 + JQEZ5 + UNC1999Combination | Melanoma | Predictive | D | Supports Sensitivity Response | 5 | rejected | EID5677Additional diseases: GC-DLBCL, Follicular lymphoma (FL). Y641 mutations are present in about 20% of GC-DLBCL, 10% FL, and 5% Melanoma (from TCGA/cBioportal). Also note that Y641 and Y646 mutations ar… (full text at CIViC) PMID 27135738 · Souroullas et al., 2016 · Open in CIViC | civic |